TrialJournal of viral hepatitis2021

Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials.

Edward Gane et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.